Novartis unveils new focused strategy

Transformation to pure-play Innovative Medicines company nears completion

Bausch and Glenmark announce approval of RYALTRIS in Canada

RYALTRIS is a fixed-dose combination therapy that provides relief for the symptoms of SAR, both nasal and ocular, in one easy-to-use nasal spray

Lynparza approved in China as first-line maintenance treatment with Bevacizumab for HRD- positive advanced ovarian cancer

One in two women with advanced ovarian cancer has an HRD-positive tumor

JB Pharma witness 20% growth in August 2022: IQVIA

Our strategy to drive therapy and brand-focused expansion will continue to show results, especially in the domestic business.

BridgeBio Pharma, Sentynl Therapeutics receive marketing authorization in the EU for fosdenopterin

NULIBRY is a first-in-class cPMP substrate replacement therapy to reduce the risk of mortality in patients with MoCD Type A.

Aster Hospitals Bangalore launches 'Aster International Institute of Oncology'

This newly launched institute will be the centre of excellence in the treatment of all cancers under a single roof.

Merck to initiate new Phase 3 clinical program for treatment of HIV-1 Infection

Phase 2 study evaluating an investigational weekly oral combination treatment regimen of islatravir and Gilead Sciences’ lenacapavir to resume with lower dose of islatravir

DAMAN enters ambitious European precision medicine healthcare project

Coordinated by the Medical University of Vienna, a consortium of 13 leading European organizations including university hospitals, research institutions and healthcare companies will conduct the 5-year project co-funded by Horizon Europe.

Tezspire approved in the EU for the treatment of severe asthma

First and only biologic approved in the EU in patients with severe asthma with no phenotype or biomarker limitations

DME market across 7MM set to reach $11.1 billion in 2031, forecasts GlobalData